Holen Sie sich die Stockscreener-App
246.27
1.16%
-2.89
Vorhandelsmarkt:
246.61
0.34
+0.14%
Schlusskurs vom Vortag:
$249.16
Offen:
$251.28
24-Stunden-Volumen:
542.93K
Relative Volume:
0.73
Marktkapitalisierung:
$31.76B
Einnahmen:
$2.09B
Nettoeinkommen (Verlust:
$-332.26M
KGV:
-94.00
EPS:
-2.62
Netto-Cashflow:
$16.06M
1W Leistung:
+3.48%
1M Leistung:
-0.13%
6M Leistung:
+2.60%
1J Leistung:
+30.61%
1-Tages-Spanne:
$245.69
$253.50
1-Wochen-Bereich:
$236.87
$261.86
52-Wochen-Spanne:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Hemophilia B Market to Show Remarkable Growth Trends from 2024 - openPR
Gateway Investment Advisers LLC Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 6.7%Here's What Happened - MarketBeat
Empirical Asset Management LLC Takes $12.15 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
FY2024 Earnings Forecast for ALNY Issued By Zacks Research - MarketBeat
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) A Risky Investment? - Simply Wall St
Burney Co. Buys 4,791 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
What is William Blair's Estimate for ALNY FY2024 Earnings? - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters ATTR-CM stock outlook - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Up 7.1%Still a Buy? - MarketBeat
Alnylam Shares Rise 8% On Preliminary Product Revenue Growth - MarketWatch
Alnylam Pharmaceuticals' (ALNY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Alnylam shares jump on strong revenue forecast and profit outlook By Investing.com - Investing.com Australia
Alnylam shares jump on strong revenue forecast and profit outlook - Investing.com
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals - Yahoo Finance
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLC - MarketBeat
What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Alnylam sees 2024 net product revenues of over $1.6B, up 33% Y/Y (NASDAQ:ALNY) - Seeking Alpha
Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR
Alnylam Reports Strong 33% Growth, Sets Ambitious $2.25B Revenue Target for 2025 - StockTitan
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2025 -January 12, 2025 at 04:00 pm EST - Marketscreener.com
Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals - MSN
Bausch + Lomb taps ex-Alnylam team's new venture for RNA eye disease programme - FirstWord Pharma
StockNews.com Downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to Hold - MarketBeat
Alpha-1 Antitrypsin Deficiency Clinical and Non-Clinical - openPR
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $310.00 at Sanford C. Bernstein - MarketBeat
City Therapeutics Appoints Andy Orth as Chief Executive Officer - BioSpace
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025 - Seeking Alpha
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
5 FDA decisions to watch in the first quarter of 2025 - BioPharma Dive
5 FDA Decisions to Watch in Q1 - BioSpace
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
2,520 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Everence Capital Management Inc. - MarketBeat
Principal Financial Group Inc. Has $2.92 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
When the Price of (ALNY) Talks, People Listen - Stock Traders Daily
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Buy at StockNews.com - MarketBeat
Exploring High Growth Tech Stocks in the US December 2024 - Simply Wall St
Dyslipidemia Market Poised for Significant Growth from 2024 - openPR
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? - MSN
How Is The Market Feeling About Alnylam Pharmaceuticals? - Benzinga
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024? - Insider Monkey
When (ALNY) Moves Investors should Listen - Stock Traders Daily
Sanctuary Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
City: Taking RNAi beyond the liver - BioCentury
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
4 Biotech Stocks Most Wall Street Analysts Are Bullish About - Yahoo Finance
Biotech CEO on RNAI and Medicine of the Future - Barron's
RNAi Technology Market to Witness Huge Growth by 2031 | Alnylam - openPR
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by StockNews.com to "Buy" Rating - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters amvuttra stock outlook - Investing.com
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
2.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):